EUCTR2006-003495-35-IT进行中（未招募）不适用
PHASE II TRIAL OF BORTEZOMIB (VELCADE) IN COMBINATION WITH CHLORAMBUCIL IN PATIENTS WITH RELAPSED/REFRACTORY WALDENSTROM?S MACROGLOBULINEMIA OR SMALL LYMPHOCYTIC LYMPHOMA. A MULTICENTER STUDY. - ND
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •?Age >= 18 years and < 70 years
- •?Histological proven diagnosis of Waldenstrom disease or Small lymphocytic lymphoma by the International Working Formulation (IWF) classification
- •?Relapsed or refractory disease pre-treated with >1 prior chemotherapy regimen (including monoclonal anti-CD20 as single treatment)
- •?Symptomatic disease
- •?Measurable or valuable disease
- •?Full recovery from previous therapy, with life expectancy of at least 6 months
- •?ECOG performance status 0-2 (ECOG see Appendix II)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •?History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological, rheumatologic, haematological,....
研究者
相似试验
进行中（未招募）
1 期
PHASE II TRIAL OF BORTEZOMIB (VELCADE®) IN PATIENTS WITH ADVANCED OR RELAPSED LYMPHOMA OF THE MUCOSA ASSOCIATED LYMPHOID TISSUE (MALT)EUCTR2005-003077-25-ATAKH Vienna16
进行中（未招募）
不适用
Phase II Study of Combination Bortezomib (VELCADE, PS-341), Dexamethasone, and Rituximab (MabThera) (BDR) in Patients with previously untreated Waldenstrom’s Macroglobulinemia (WM). - protocol BDRewly diagnosed Waldenstrom's macroglobulinemia (WM)MedDRA version: 8.1Level: LLTClassification code 10054695Term: Waldenstrom's macroglobulinemiaEUCTR2006-003563-31-NLEuropean Myeloma Network90
进行中（未招募）
不适用
Phase II Study of Combination Bortezomib (VELCADE, PS-341), Dexamethasone, and Rituximab (MabThera) (BDR) in Patients with previously untreated Waldenstrom’s Macroglobulinemia (WM). - protocol BDREUCTR2006-003563-31-DKEuropean Myeloma Network90
进行中（未招募）
不适用
A phase II Study of Bortezomib (Velcade), a proteasome Inhibitor, in treating patients with idiopathic Myelofibrosis (IM) randomized to receive new investigational drugs. - NDMedDRA version: 6.1Level: PTClassification code 10028537idiopathic myelofibrosisEUCTR2006-001462-16-ITOSPEDALE POLICLINICO S. MATTEO35
进行中（未招募）
不适用
A PHASE II STUDY OF VELCADE BORTEZOMIB - PS341 IN THE TREATMENT OF PATIENTS OVER 18 YEARS WITH Ph LEUKEMIApatients over 18 years with Ph leukaemiaMedDRA version: 9.1Level: LLTClassification code 10009013Term: Chronic myeloid leukaemiaEUCTR2004-002977-22-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI